Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| Weiss Ratings | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.86 | |||
| Price History | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.76% | |||
| 30-Day Total Return | -12.29% | |||
| 60-Day Total Return | -14.65% | |||
| 90-Day Total Return | -0.78% | |||
| Year to Date Total Return | -11.93% | |||
| 1-Year Total Return | -43.40% | |||
| 2-Year Total Return | -15.11% | |||
| 3-Year Total Return | 1.60% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -48.62% | |||
| 52-Week Low % Change | 13.39% | |||
| Price | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.36 | |||
| 52-Week Low Price | $5.60 | |||
| 52-Week Low Price (Date) | Nov 22, 2024 | |||
| 52-Week High Price (Date) | Feb 18, 2025 | |||
| Valuation | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.55B | |||
| Enterprise Value | 2.07B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.66 | |||
| Earnings Per Share Growth | 5.88% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 36.29 | |||
| Price/Book (Q) | 2.44 | |||
| Enterprise Value/Revenue (TTM) | 35.16 | |||
| Price | $6.35 | |||
| Enterprise Value/EBITDA (TTM) | -4.67 | |||
| Enterprise Value/EBIT | -4.32 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 336.04M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 385 269 0203 | |||
| Address | 41 South Rio Grande Street Salt Lake City, UT 84101 | |||
| Website | www.recursion.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -814.09% | |||
| Profit Margin | -788.01% | |||
| Management Effectiveness | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -28.48% | |||
| Return on Equity | -- | |||
| Income Statement | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 58.84M | |||
| Total Revenue (TTM) | 58.84M | |||
| Revenue Per Share | $0.18 | |||
| Gross Profit (TTM) | -300.82M | |||
| EBITDA (TTM) | -442.51M | |||
| EBIT (TTM) | -479.01M | |||
| Net Income (TTM) | -463.66M | |||
| Net Income Avl. to Common (TTM) | -463.66M | |||
| Total Revenue Growth (Q YOY) | -58.26% | |||
| Earnings Growth (Q YOY) | -92.38% | |||
| EPS Diluted (TTM) | -1.66 | |||
| EPS Diluted Growth (Q YOY) | -28.41% | |||
| Balance Sheet | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 594.35M | |||
| Cash Per Share (Q) | $1.77 | |||
| Total Current Assets (Q) | 714.27M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.03B | |||
| Current Ratio (Q) | 3.810 | |||
| Book Value Per Share (Q) | $2.61 | |||
| Total Assets (Q) | 1.45B | |||
| Total Current Liabilities (Q) | 187.47M | |||
| Total Debt (Q) | 108.49M | |||
| Total Liabilities (Q) | 413.82M | |||
| Total Common Equity (Q) | 1.03B | |||
| Cash Flow | RXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 260.06M | |||
| Cash from Financing (TTM) | 304.12M | |||
| Net Change in Cash (TTM) | 201.60M | |||
| Levered Free Cash Flow (TTM) | -194.85M | |||
| Cash from Operations (TTM) | -359.17M | |||
